Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Oncogene-induced senescence in hematopoietic progenitors features myeloid restricted hematopoiesis, chronic inflammation and histiocytosis

Open access

Abstract

Activating mutations in the BRAF-MAPK pathway have been reported in histiocytoses, hematological inflammatory neoplasms characterized by multi-organ dissemination of pro-inflammatory myeloid cells. Here, we generate a humanized mouse model of transplantation of human hematopoietic stem and progenitor cells (HSPCs) expressing the activated form of BRAF (BRAFV600E). All mice transplanted with BRAFV600E-expressing HSPCs succumb to bone marrow failure, displaying myeloid-restricted hematopoiesis and multi-organ dissemination of aberrant mononuclear phagocytes. At the basis of this aggressive phenotype, we uncover the engagement of a senescence program, characterized by DNA damage response activation and a senescence-associated secretory phenotype, which affects also non-mutated bystander cells. Mechanistically, we identify TNFα as a key determinant of paracrine senescence and myeloid-restricted hematopoiesis and show that its inhibition dampens inflammation, delays disease onset and rescues hematopoietic defects in bystander cells. Our work establishes that senescence in the human hematopoietic system links oncogene-activation to the systemic inflammation observed in histiocytic neoplasms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-24876-1

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 BRAFV600E activation in human HSPCs leads to lethal bone marrow aplasia and histiocytosis. Schematic representation of lentiviral vectors (a) and experimental strategy (b) employed. c In vitro transduction level of GFP (green), wtBRAF (blue), and BRAFV600E-expressing HSPCs (red). d Disease-free survival curves from CTRL group (mice receiving untransduced HSPCs (black, n = 3)), GFP only (green, n = 12), wtBRAF-expressing HSPCs (blue, n = 13), and mice transplanted with BRAFV600E-expressing HSPCs (red) at different transduction levels (<30%, dashed line, n = 10 and >30%, continuous line, n = 17). Statistical test: log-rank (Mantel−Cox) test between survival curves of the low (<30% BRAFV600E-expressing HSPCs) and high (>30% BRAFV600E-expressing HSPCs) dose BRAFV600E groups. ****p < 0.0001. e Representative images of femur and spleen from mice transplanted with wtBRAF and BRAFV600E-expressing HSPCs at the time of sacrifice. f Number of cells in femurs of mice transplanted with untransduced (UT, black, n = 4), wtBRAF (blue, n = 17) or BRAFV600E (red, n = 17)-expressing HSPCs. Data presented as mean values +/− SEM. Statistical test: Kruskal−Wallis with Dunn’s multiple comparisons ****p = 0.0001; ns non significant. g Immunohistochemical analysis of a lung lesion from a representative mouse transplanted with BRAFV600E-expressing HSPCs at the time of sacrifice. Lung morphology analyzed by hematoxylin and eosin staining. A lung of a mouse transplanted with wtBRAF-expressing HSPCs was used as control. Markers for immunohistochemistry include: CD14 for monocytes, CD1a for myeloid dendritic cells, CD68/PGM1 for large macrophages, S100 for dendritic cells, and CD207 for smaller dendritic cells. Scale bars: 50 or 300 µm. (n = 4 mice for wtBRAF and n = 3 mice for BRAFV600E group).
Fig. 1 BRAFV600E activation in human HSPCs leads to lethal bone marrow aplasia and histiocytosis. Schematic representation of lentiviral vectors (a) and experimental strategy (b) employed. c In vitro transduction level of GFP (green), wtBRAF (blue), and BRAFV600E-expressing HSPCs (red). d Disease-free survival curves from CTRL group (mice receiving untransduced HSPCs (black, n = 3)), GFP only (green, n = 12), wtBRAF-expressing HSPCs (blue, n = 13), and mice transplanted with BRAFV600E-expressing HSPCs (red) at different transduction levels (<30%, dashed line, n = 10 and >30%, continuous line, n = 17). Statistical test: log-rank (Mantel−Cox) test between survival curves of the low (<30% BRAFV600E-expressing HSPCs) and high (>30% BRAFV600E-expressing HSPCs) dose BRAFV600E groups. ****p < 0.0001. e Representative images of femur and spleen from mice transplanted with wtBRAF and BRAFV600E-expressing HSPCs at the time of sacrifice. f Number of cells in femurs of mice transplanted with untransduced (UT, black, n = 4), wtBRAF (blue, n = 17) or BRAFV600E (red, n = 17)-expressing HSPCs. Data presented as mean values +/− SEM. Statistical test: Kruskal−Wallis with Dunn’s multiple comparisons ****p = 0.0001; ns non significant. g Immunohistochemical analysis of a lung lesion from a representative mouse transplanted with BRAFV600E-expressing HSPCs at the time of sacrifice. Lung morphology analyzed by hematoxylin and eosin staining. A lung of a mouse transplanted with wtBRAF-expressing HSPCs was used as control. Markers for immunohistochemistry include: CD14 for monocytes, CD1a for myeloid dendritic cells, CD68/PGM1 for large macrophages, S100 for dendritic cells, and CD207 for smaller dendritic cells. Scale bars: 50 or 300 µm. (n = 4 mice for wtBRAF and n = 3 mice for BRAFV600E group).CC BY · PubMed Central
Fig. 2 BRAFV600E expression in human HSPCs results in a dose-dependent lymphoid impairment. Percentage of (a) GFP+ cells within the human graft (hCD45+), (b) human engrafted cells in total BM and (c) myeloid (CD33+) and (d) lymphoid B cells (CD19+) within the human graft at euthanasia, in the BM of mice transplanted with CTRL (wtBRAF or GFP only, blue, n = 31) and BRAFV600E (red, n = 25) cells. Data are presented as mean +/− SD. Statistical test: Two-tailed Mann−Whitney. e Percentage of myeloid GFP+ (red, dashed green) and myeloid GFP− (red), B (CD19+) cells GFP− (blue) and B cells GFP+ (blue, dashed green) within total BM from mice transplanted with CTRL or BRAFV600E HSPCs. Values on x-axis were ordered by transduction level. Percentage of GFP+ and GFP− (f) B cells or (g) myeloid cells within total BM from mice transplanted with CTRL (blue, n = 31 for left panel, n = 22 for mid and right panel) and BRAFV600E-expressing (red, n = 25) HSPCs. Data are represented as mean values +/− SD. Statistical test: two-tailed Mann−Whitney. h Percentage of GFP+ and GFP− CD19+ cells with respect to CD45+/GFP+ in each mouse. Exponential regression analysis. The goodness of fit measured as R2. i Time-course of infiltration grade in organs from mice of the wtBRAF (blue) and BRAFV600E (red) groups; n = 3 for each time point. Data are presented as mean +/− SD. Spleen: dashed line, circles; liver: dashed line, squares; lung: dashed line, triangles; BM: continuous line, dots. j Time-course analyses of the percentage of GFP+ and GFP− myeloid and B cells in BM of mice transplanted with wtBRAF or BRAFV600E HSPCs; n = 3 each time point. Data are presented as mean +/− SD, see (e) for color code. k–p Percentage of human HSPCs subpopulations within GFP− and GFP+ cells in BM cells harvested from mice at 9 and 14 days after transplant with CTRL (untransduced, blue, n = 2 for each time point), wtBRAF (blue, n = 5 for each time point) and BRAFV600E (red, n = 5 for each time point) HSPCs. Data are presented as mean +/− SD (HSPC hematopoietic stem and progenitor cells; HSC hematopoietic stem cells; MLP multi-lymphoid progenitors; PreBNK B and NK cell progenitors; CMP common-myeloid progenitors; GMP granulocyte/monocyte progenitors). Statistical analysis between groups by two-tailed Mann−Whitney test. ns non-significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
Fig. 2 BRAFV600E expression in human HSPCs results in a dose-dependent lymphoid impairment. Percentage of (a) GFP+ cells within the human graft (hCD45+), (b) human engrafted cells in total BM and (c) myeloid (CD33+) and (d) lymphoid B cells (CD19+) within the human graft at euthanasia, in the BM of mice transplanted with CTRL (wtBRAF or GFP only, blue, n = 31) and BRAFV600E (red, n = 25) cells. Data are presented as mean +/− SD. Statistical test: Two-tailed Mann−Whitney. e Percentage of myeloid GFP+ (red, dashed green) and myeloid GFP− (red), B (CD19+) cells GFP− (blue) and B cells GFP+ (blue, dashed green) within total BM from mice transplanted with CTRL or BRAFV600E HSPCs. Values on x-axis were ordered by transduction level. Percentage of GFP+ and GFP− (f) B cells or (g) myeloid cells within total BM from mice transplanted with CTRL (blue, n = 31 for left panel, n = 22 for mid and right panel) and BRAFV600E-expressing (red, n = 25) HSPCs. Data are represented as mean values +/− SD. Statistical test: two-tailed Mann−Whitney. h Percentage of GFP+ and GFP− CD19+ cells with respect to CD45+/GFP+ in each mouse. Exponential regression analysis. The goodness of fit measured as R2. i Time-course of infiltration grade in organs from mice of the wtBRAF (blue) and BRAFV600E (red) groups; n = 3 for each time point. Data are presented as mean +/− SD. Spleen: dashed line, circles; liver: dashed line, squares; lung: dashed line, triangles; BM: continuous line, dots. j Time-course analyses of the percentage of GFP+ and GFP− myeloid and B cells in BM of mice transplanted with wtBRAF or BRAFV600E HSPCs; n = 3 each time point. Data are presented as mean +/− SD, see (e) for color code. k–p Percentage of human HSPCs subpopulations within GFP− and GFP+ cells in BM cells harvested from mice at 9 and 14 days after transplant with CTRL (untransduced, blue, n = 2 for each time point), wtBRAF (blue, n = 5 for each time point) and BRAFV600E (red, n = 5 for each time point) HSPCs. Data are presented as mean +/− SD (HSPC hematopoietic stem and progenitor cells; HSC hematopoietic stem cells; MLP multi-lymphoid progenitors; PreBNK B and NK cell progenitors; CMP common-myeloid progenitors; GMP granulocyte/monocyte progenitors). Statistical analysis between groups by two-tailed Mann−Whitney test. ns non-significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.CC BY · PubMed Central
Fig. 3 Global gene expression analysis upon oncogene-activation. a Principal component analysis (PCA) of transcriptional profiles of sorted human myeloid cells (CD33+) GFP+ and GFP− fractions from control mice, transplanted with human HSPCs transduced with GFP (light pink for GFP− and dark pink for GFP+), wtBRAF (light red for GFP− and dark red for GFP+) or untransduced cells (salmon), and mice transplanted with BRAFV600E-expressing HSPCs at 16 days post-transplantation (green for GFP+ and blu for GFP− cells). b Unsupervised clustering analysis of DEGs in the different experimental groups. c, d Volcano plots highlighting significant downregulated (green) and upregulated (red) genes in sorted human myeloid cells (CD33+) from the BRAFV600E mice group (both GFP+/− fractions) compared to controls. The gene symbols of the top 15 upregulated and the top ten downregulated genes based on adjusted p-value are indicated. Statistical test: two-sided exact test for negative-binomial distribution, the Benjamini and Hochberg’s approach has been used for controlling the false discovery rate (FDR). e Venn Diagram representation of upregulated and downregulated DEGs in GFP+ and GFP− CD33+ cells of the BRAFV600E group showing that about 90% of the DEGs in the GFP− fraction were also deregulated in the GFP+ fraction. f Gene set enrichment analysis (GSEA) of sorted CD33+/GFP+ and CD33+/GFP− cells from the BRAFV600E group. Normalized enrichment score (NES) is indicated.
Fig. 3 Global gene expression analysis upon oncogene-activation. a Principal component analysis (PCA) of transcriptional profiles of sorted human myeloid cells (CD33+) GFP+ and GFP− fractions from control mice, transplanted with human HSPCs transduced with GFP (light pink for GFP− and dark pink for GFP+), wtBRAF (light red for GFP− and dark red for GFP+) or untransduced cells (salmon), and mice transplanted with BRAFV600E-expressing HSPCs at 16 days post-transplantation (green for GFP+ and blu for GFP− cells). b Unsupervised clustering analysis of DEGs in the different experimental groups. c, d Volcano plots highlighting significant downregulated (green) and upregulated (red) genes in sorted human myeloid cells (CD33+) from the BRAFV600E mice group (both GFP+/− fractions) compared to controls. The gene symbols of the top 15 upregulated and the top ten downregulated genes based on adjusted p-value are indicated. Statistical test: two-sided exact test for negative-binomial distribution, the Benjamini and Hochberg’s approach has been used for controlling the false discovery rate (FDR). e Venn Diagram representation of upregulated and downregulated DEGs in GFP+ and GFP− CD33+ cells of the BRAFV600E group showing that about 90% of the DEGs in the GFP− fraction were also deregulated in the GFP+ fraction. f Gene set enrichment analysis (GSEA) of sorted CD33+/GFP+ and CD33+/GFP− cells from the BRAFV600E group. Normalized enrichment score (NES) is indicated.CC BY · PubMed Central
Fig. 4 BRAFV600E expression in HSPCs induces p16 expression and cell cycle arrest. a Representative images of p16 (red) and DAPI (blue) positive cells in BM of mice transplanted with wtBRAF and BRAFV600E-expressing HSPCs at the time of euthanasia. Scale bar: 20 µm. b Quantification of p16+ cells from (A), wtBRAF (blue, n = 3), and BRAFV600E (red, n = 2) groups. Each symbol indicates independent measurements from a given mouse. Lines indicate mean values ± SEM. c Representative images of p16 (red) and DAPI (blue) positive in wtBRAF and BRAFV600E-expressing HSPCs 120 h after in vitro transduction. Scale bar: 50 µm. d Quantification of p16+ cells from (c); wtBRAF (blue) and BRAFV600E (red): n = 4. Lines indicate mean values ± SEM. Statistical test: two-tailed Mann−Whitney. *p < 0.05. e Representative images of 53BP1 foci (red) and DAPI (blue) in wtBRAF and BRAFV600E-expressing HSPCs 120 h post-transduction. f Quantification of 53BP1 foci from (e); wtBRAF (blue, n = 5); BRAFV600E (red, n = 5). Lines indicate mean values ± SEM. Statistical test: Two-tailed Mann−Whitney **p < 0.01 (p = 0.0079). g Growth curves of wtBRAF or BRAFV600E-expressing HSPCs. Cells were counted at the indicated time points after transduction. wtBRAF (n = 8 repeated measurements for four independent donors); BRAFV600E (n = 8 repeated measurements for four independent donors). Data are presented as mean +/− SD. Linear mixed-effects model (LME) followed by post hoc analysis at 48 and 216 h (****p < 0.0001). Inset indicates growth curves of BRAFV600E compared to wtBRAF at early time points. See also Source Data file. h Clonogenic potential of wtBRAF and BRAFV600E-expressing HSPCs in methylcellulose assays over time. wtBRAF (n = 8 repeated measurements for four independent donors); BRAFV600E (n = 8 repeated measurements for four independent donors). Data are presented as mean values +/− SEM. Linear mixed-effects model (LME). ****p < 0.0001. See also Source Data file. All graphs in this figure display data from wtBRAF in blue and from BRAFV600E in red.
Fig. 4 BRAFV600E expression in HSPCs induces p16 expression and cell cycle arrest. a Representative images of p16 (red) and DAPI (blue) positive cells in BM of mice transplanted with wtBRAF and BRAFV600E-expressing HSPCs at the time of euthanasia. Scale bar: 20 µm. b Quantification of p16+ cells from (A), wtBRAF (blue, n = 3), and BRAFV600E (red, n = 2) groups. Each symbol indicates independent measurements from a given mouse. Lines indicate mean values ± SEM. c Representative images of p16 (red) and DAPI (blue) positive in wtBRAF and BRAFV600E-expressing HSPCs 120 h after in vitro transduction. Scale bar: 50 µm. d Quantification of p16+ cells from (c); wtBRAF (blue) and BRAFV600E (red): n = 4. Lines indicate mean values ± SEM. Statistical test: two-tailed Mann−Whitney. *p < 0.05. e Representative images of 53BP1 foci (red) and DAPI (blue) in wtBRAF and BRAFV600E-expressing HSPCs 120 h post-transduction. f Quantification of 53BP1 foci from (e); wtBRAF (blue, n = 5); BRAFV600E (red, n = 5). Lines indicate mean values ± SEM. Statistical test: Two-tailed Mann−Whitney **p < 0.01 (p = 0.0079). g Growth curves of wtBRAF or BRAFV600E-expressing HSPCs. Cells were counted at the indicated time points after transduction. wtBRAF (n = 8 repeated measurements for four independent donors); BRAFV600E (n = 8 repeated measurements for four independent donors). Data are presented as mean +/− SD. Linear mixed-effects model (LME) followed by post hoc analysis at 48 and 216 h (****p < 0.0001). Inset indicates growth curves of BRAFV600E compared to wtBRAF at early time points. See also Source Data file. h Clonogenic potential of wtBRAF and BRAFV600E-expressing HSPCs in methylcellulose assays over time. wtBRAF (n = 8 repeated measurements for four independent donors); BRAFV600E (n = 8 repeated measurements for four independent donors). Data are presented as mean values +/− SEM. Linear mixed-effects model (LME). ****p < 0.0001. See also Source Data file. All graphs in this figure display data from wtBRAF in blue and from BRAFV600E in red.CC BY · PubMed Central
Fig. 5 BRAFV600E-mediated oncogene-induced senescence in histiocytic lesions and in human grafts. a Immunohistochemical analysis of serial sections of lungs lesions from a representative mouse transplanted with BRAFV600E-expressing HSPCs at the time of sacrifice. Markers for immunohistochemistry include: GFP for vector marking, p16 for senescence/cell cycle arrest, S100, CD207, and PGM1 for dendritic cells and macrophages. Tissue morphology analyzed by hematoxylin and eosin (H&E). Yellow boxes indicate zoom-in areas. Scale bars: 300 or 50 µm. n = 1 representative mouse. b Representative immunohistochemical analysis for p16 expression in lung sections from mice transplanted with wtBRAF or BRAFV600E-expressing HSPCs harvested at 9 and 24 days after transplantation. Immunofluorescence analysis for p16 (red) and the proliferation marker Ki67 (green) in lung lesions from a mouse of the BRAFV600E group at 24 days post-transplantation. (n = 3 for each time point). Nuclei stained by DAPI (blu). Scale bar: 50 µm. c, d Frequency (in percentage) of GFP+ or GFP− human myeloid cells (CD33+) which express the senescence markers p16 (c) or SA-β-gal (d). FACS analysis was performed on BM cells obtained at euthanasia from mice transplanted with wtBRAF (blue) or BRAFV600E (red) HSPCs (n = 17 each group). Data are presented as mean values +/− SEM. Statistical test: two-tailed Mann−Whitney ****p < 0.0001, *p < 0.05. e Representative images of a skin lesion from a patient with histiocytosis stained for p16 (positive ∼85%), BRAFV600E (VE1) (positive ∼25%), Ki67 (positive <1%), and SA-β-Gal (positive ∼48%). Tissue morphology was analyzed by hematoxylin and eosin. Scale bars: 100 or 200 µm.
Fig. 5 BRAFV600E-mediated oncogene-induced senescence in histiocytic lesions and in human grafts. a Immunohistochemical analysis of serial sections of lungs lesions from a representative mouse transplanted with BRAFV600E-expressing HSPCs at the time of sacrifice. Markers for immunohistochemistry include: GFP for vector marking, p16 for senescence/cell cycle arrest, S100, CD207, and PGM1 for dendritic cells and macrophages. Tissue morphology analyzed by hematoxylin and eosin (H&E). Yellow boxes indicate zoom-in areas. Scale bars: 300 or 50 µm. n = 1 representative mouse. b Representative immunohistochemical analysis for p16 expression in lung sections from mice transplanted with wtBRAF or BRAFV600E-expressing HSPCs harvested at 9 and 24 days after transplantation. Immunofluorescence analysis for p16 (red) and the proliferation marker Ki67 (green) in lung lesions from a mouse of the BRAFV600E group at 24 days post-transplantation. (n = 3 for each time point). Nuclei stained by DAPI (blu). Scale bar: 50 µm. c, d Frequency (in percentage) of GFP+ or GFP− human myeloid cells (CD33+) which express the senescence markers p16 (c) or SA-β-gal (d). FACS analysis was performed on BM cells obtained at euthanasia from mice transplanted with wtBRAF (blue) or BRAFV600E (red) HSPCs (n = 17 each group). Data are presented as mean values +/− SEM. Statistical test: two-tailed Mann−Whitney ****p < 0.0001, *p < 0.05. e Representative images of a skin lesion from a patient with histiocytosis stained for p16 (positive ∼85%), BRAFV600E (VE1) (positive ∼25%), Ki67 (positive <1%), and SA-β-Gal (positive ∼48%). Tissue morphology was analyzed by hematoxylin and eosin. Scale bars: 100 or 200 µm.CC BY · PubMed Central
Fig. 6 Dissection of the contribution of cell cycle arrest and SASP in BRAFV600E-expressing HSPCs. a Experimental strategy adopted to dissect p16 and SASP induction. Relative mRNA expression of (b) p16 and (c) p21 upon treatment with scrambled (scr) shRNA or shRNA against p16/ARF (shp16). Data are presented as mean +/− SEM. Each dot represents an independent donor (n = 4). Statistical test: Kruskal−Wallis with Dunn’s multiple comparison. d Growth curves of wtBRAF or BRAFV600E-expressing HSPCs depleted or not for p16. n = 4 independent donors. Data are presented as mean +/− SD. Statistical test: Kruskal-Wallis with Dunn’s multiple comparison at 48 and 216 h. Inset indicates growth curves at early time points. e Percentage of GFP+ cells of wtBRAF or BRAFV600E-expressing HSPCs depleted or not for p16. Data are presented as mean +/− SD. Each dot represents an independent donor (n = 4). Statistical test: Kruskal−Wallis with Dunn’s multiple comparison. f Clonogenic potential upon treatment with scr or shp16, in methylcellulose assays at 120 h post transduction, wtBRAF: n = 12 repeated measurements for four independent donors; BRAFV600E: n = 12 repeated measurements for four independent donors. Statistical test: Two-tailed Mann−Whitney. g–k Gene expression analysis of SASP cytokines (IL1α, IL1β, IL8, TNFα, and MCP1) in wtBRAF or BRAFV600E-expressing cells upon treatment with scr or shp16. Data are presented as mean +/− SEM. Each dot represents an independent donor transduced with BRAFV600E (N = 4). Statistical test: Two-tailed Mann−Whitney. l Clonogenic potential of wtBRAF and BRAFV600E-expressing HSPCs upon treatment with scrambled shRNA (scr) or shRNA against RELA/p65 (shp65) in methylcellulose assays at 120 h post transduction with wtBRAF or BRAFV600E vectors. n = 12 repeated measurements for four independent donors in each group. Data are presented as mean +/− SEM. Statistical test: Two-tailed Mann−Whitney. All graphs in this figure display data from: wtBRAF treated with scr in dark blue or with shRNA either against p16 in light blue; BRAFV600E treated with scr in dark red or with shRNA either against p16 in light red. Gene expression values are represented as 2^−ΔCt relative to housekeeping gene. *p < 0.05; **p < 0.01; ****p < 0.0001.
Fig. 6 Dissection of the contribution of cell cycle arrest and SASP in BRAFV600E-expressing HSPCs. a Experimental strategy adopted to dissect p16 and SASP induction. Relative mRNA expression of (b) p16 and (c) p21 upon treatment with scrambled (scr) shRNA or shRNA against p16/ARF (shp16). Data are presented as mean +/− SEM. Each dot represents an independent donor (n = 4). Statistical test: Kruskal−Wallis with Dunn’s multiple comparison. d Growth curves of wtBRAF or BRAFV600E-expressing HSPCs depleted or not for p16. n = 4 independent donors. Data are presented as mean +/− SD. Statistical test: Kruskal-Wallis with Dunn’s multiple comparison at 48 and 216 h. Inset indicates growth curves at early time points. e Percentage of GFP+ cells of wtBRAF or BRAFV600E-expressing HSPCs depleted or not for p16. Data are presented as mean +/− SD. Each dot represents an independent donor (n = 4). Statistical test: Kruskal−Wallis with Dunn’s multiple comparison. f Clonogenic potential upon treatment with scr or shp16, in methylcellulose assays at 120 h post transduction, wtBRAF: n = 12 repeated measurements for four independent donors; BRAFV600E: n = 12 repeated measurements for four independent donors. Statistical test: Two-tailed Mann−Whitney. g–k Gene expression analysis of SASP cytokines (IL1α, IL1β, IL8, TNFα, and MCP1) in wtBRAF or BRAFV600E-expressing cells upon treatment with scr or shp16. Data are presented as mean +/− SEM. Each dot represents an independent donor transduced with BRAFV600E (N = 4). Statistical test: Two-tailed Mann−Whitney. l Clonogenic potential of wtBRAF and BRAFV600E-expressing HSPCs upon treatment with scrambled shRNA (scr) or shRNA against RELA/p65 (shp65) in methylcellulose assays at 120 h post transduction with wtBRAF or BRAFV600E vectors. n = 12 repeated measurements for four independent donors in each group. Data are presented as mean +/− SEM. Statistical test: Two-tailed Mann−Whitney. All graphs in this figure display data from: wtBRAF treated with scr in dark blue or with shRNA either against p16 in light blue; BRAFV600E treated with scr in dark red or with shRNA either against p16 in light red. Gene expression values are represented as 2^−ΔCt relative to housekeeping gene. *p < 0.05; **p < 0.01; ****p < 0.0001.CC BY · PubMed Central
Fig. 7 SASP factors from senescent HSPCs induce paracrine senescence in non-oncogene-expressing cells. Concentrations of human pro-inflammatory factors in (a) blood serum of mice at euthanasia or (b) in cultured media 120 h post-transduction. For (a), each dot represents a mouse: untreated (UT, black, n = 2), GFP (green, n = 13), wtBRAF (blue, n = 4), BRAFV600E (red, n = 13). For (b), wtBRAF (blue), and BRAFV600E (red), four donors for each group. Data are presented as box plots minimum to maximum with lines representing means. c Correlation between blood cytokine levels and survival of BRAFV600E mice (n = 11). Non-linear regression one-phase decay. The goodness of fit: R2. d Growth curve of HSPCs exposed to CM from wtBRAF or BRAFV600E HSPCs. n = 9 for three donors/group. Data are presented as mean values +/− SD. e Clonogenic potential of HSPCs exposed to CM from wtBRAF or BRAFV600E HSPCs. n = 7 for three donors/group. Data are presented as mean values +/− SEM. f–h Growth curves of HSPCs exposed to cytokines: (f) IL1α (light green: 0.5 ng/ml, medium green: 5 ng/ml and dark green: 50 ng/ml), (g) IL1β (light blue: 0.5 ng/ml, medium blue: 5 ng/ml and dark blue: 50 ng/ml) and (h) TNFα (light red: 0.5 ng/ml, medium red: 5 ng/ml and dark red: 50 ng/ml). Technical replicates: CTRL (n = 5), IL1α-IL1β-TNFα (n = 4). CTRL values (black) are repeated in f, g, and h. Data are presented as mean values +/− SD. Statistical test: linear mixed-effects model (LME), followed by post hoc analysis at 24 and 192 h. See also Source Data file. i Clonogenic potential of HSPCs treated with recombinant cytokines for 96 h. CTRL(n = 4), IL1α (n = 4), IL1β (n = 4), TNFα (n = 4). Data are presented as mean values +/− SEM. j Gene expression analysis of p21, IL1α, MCP1, and IL8 upon cytokine treatments (three donors for: CTRL, IL1α0.5, IL1α5, IL1α50, IL1β0.5, and TNFα0.5; four donors for: IL1β5, IL1β50, TNFα5, and TNFα50). Data are presented as mean +/− SD. k Representative images of a skin lesion from an histiocytosis patient stained for TNFα. Tissue morphology analyzed by hematoxylin and eosin (H/E). Scale bars: 100 or 200 µm. Statistical tests: for (b), two-tailed Mann−Whitney; for a, i, j, Kruskal−Wallis with post-Dunn’s multiple comparisons. ns non significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
Fig. 7 SASP factors from senescent HSPCs induce paracrine senescence in non-oncogene-expressing cells. Concentrations of human pro-inflammatory factors in (a) blood serum of mice at euthanasia or (b) in cultured media 120 h post-transduction. For (a), each dot represents a mouse: untreated (UT, black, n = 2), GFP (green, n = 13), wtBRAF (blue, n = 4), BRAFV600E (red, n = 13). For (b), wtBRAF (blue), and BRAFV600E (red), four donors for each group. Data are presented as box plots minimum to maximum with lines representing means. c Correlation between blood cytokine levels and survival of BRAFV600E mice (n = 11). Non-linear regression one-phase decay. The goodness of fit: R2. d Growth curve of HSPCs exposed to CM from wtBRAF or BRAFV600E HSPCs. n = 9 for three donors/group. Data are presented as mean values +/− SD. e Clonogenic potential of HSPCs exposed to CM from wtBRAF or BRAFV600E HSPCs. n = 7 for three donors/group. Data are presented as mean values +/− SEM. f–h Growth curves of HSPCs exposed to cytokines: (f) IL1α (light green: 0.5 ng/ml, medium green: 5 ng/ml and dark green: 50 ng/ml), (g) IL1β (light blue: 0.5 ng/ml, medium blue: 5 ng/ml and dark blue: 50 ng/ml) and (h) TNFα (light red: 0.5 ng/ml, medium red: 5 ng/ml and dark red: 50 ng/ml). Technical replicates: CTRL (n = 5), IL1α-IL1β-TNFα (n = 4). CTRL values (black) are repeated in f, g, and h. Data are presented as mean values +/− SD. Statistical test: linear mixed-effects model (LME), followed by post hoc analysis at 24 and 192 h. See also Source Data file. i Clonogenic potential of HSPCs treated with recombinant cytokines for 96 h. CTRL(n = 4), IL1α (n = 4), IL1β (n = 4), TNFα (n = 4). Data are presented as mean values +/− SEM. j Gene expression analysis of p21, IL1α, MCP1, and IL8 upon cytokine treatments (three donors for: CTRL, IL1α0.5, IL1α5, IL1α50, IL1β0.5, and TNFα0.5; four donors for: IL1β5, IL1β50, TNFα5, and TNFα50). Data are presented as mean +/− SD. k Representative images of a skin lesion from an histiocytosis patient stained for TNFα. Tissue morphology analyzed by hematoxylin and eosin (H/E). Scale bars: 100 or 200 µm. Statistical tests: for (b), two-tailed Mann−Whitney; for a, i, j, Kruskal−Wallis with post-Dunn’s multiple comparisons. ns non significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.CC BY · PubMed Central
Fig. 8 TNFα inhibition rescues paracrine HSPC dysfunction upon oncogene activation. a Schematic representation of cell treatments with conditioned medium derived from HSPCs transduced with wtBRAF or BRAFV600E lentiviral vectors, treated or not with a TNFα inhibitor (Infliximab; IFX) at the indicated concentration and time points. b Growth curve of HSPCs cultured with CM derived from HSPCs transduced with wtBRAF (dark blue) and BRAFV600E (dark red) treated or not with IFX (light blue for wtBRAF and light red for BRAFV600E). n = 9 measurements for three donors in all groups. Untreated samples are same as in Fig. 7d. Data are presented as mean values +/− SD. c Heatmap representation of gene expression analysis of senescence-associated markers in CM-treated HSPCs. Untreated n = 4, treated n = 3 biological replicates. d Clonogenic potential of HSPCs cultured with CM from transduced HSPC treated with IFX for 48-72-168-192 h: three measurements for n = 1 in all groups; 72−96 h: nine measurements for n = 3 independent donors in all groups. Untreated samples are same as in Fig. 7e. Data are presented as mean values +/− SD. e Disease-free survival analysis of mice transplanted with BRAFV600E HSPCs upon treatment with IFX (CTRL = 4 mice, blue; BRAFV600E = 9 mice, red continuous line; BRAFV600E + IFX = 10 mice, red dashed line). Log-rank test between IFX treated and untreated mice from the BRAFV600E group. **p < 0.01. Immunophenotypical analysis of (f) myeloid output (CD33+) or (g) lymphoid output (CD19+) with GFP+ and GFP− lineage for each experimental group. (CTRL = 4 mice, blue for wtBRAF and black for UT; BRAFV600E = 9 mice, red; BRAFV600E + IFX = 10 mice, light red). Data are presented as mean values +/− SD. Statistical test: Kruskal−Wallis with Dunn’s multiple comparisons comparing to BRAFV600E group. *p < 0.05;**p < 0.01; ***p < 0.001; ns non-significant.
Fig. 8 TNFα inhibition rescues paracrine HSPC dysfunction upon oncogene activation. a Schematic representation of cell treatments with conditioned medium derived from HSPCs transduced with wtBRAF or BRAFV600E lentiviral vectors, treated or not with a TNFα inhibitor (Infliximab; IFX) at the indicated concentration and time points. b Growth curve of HSPCs cultured with CM derived from HSPCs transduced with wtBRAF (dark blue) and BRAFV600E (dark red) treated or not with IFX (light blue for wtBRAF and light red for BRAFV600E). n = 9 measurements for three donors in all groups. Untreated samples are same as in Fig. 7d. Data are presented as mean values +/− SD. c Heatmap representation of gene expression analysis of senescence-associated markers in CM-treated HSPCs. Untreated n = 4, treated n = 3 biological replicates. d Clonogenic potential of HSPCs cultured with CM from transduced HSPC treated with IFX for 48-72-168-192 h: three measurements for n = 1 in all groups; 72−96 h: nine measurements for n = 3 independent donors in all groups. Untreated samples are same as in Fig. 7e. Data are presented as mean values +/− SD. e Disease-free survival analysis of mice transplanted with BRAFV600E HSPCs upon treatment with IFX (CTRL = 4 mice, blue; BRAFV600E = 9 mice, red continuous line; BRAFV600E + IFX = 10 mice, red dashed line). Log-rank test between IFX treated and untreated mice from the BRAFV600E group. **p < 0.01. Immunophenotypical analysis of (f) myeloid output (CD33+) or (g) lymphoid output (CD19+) with GFP+ and GFP− lineage for each experimental group. (CTRL = 4 mice, blue for wtBRAF and black for UT; BRAFV600E = 9 mice, red; BRAFV600E + IFX = 10 mice, light red). Data are presented as mean values +/− SD. Statistical test: Kruskal−Wallis with Dunn’s multiple comparisons comparing to BRAFV600E group. *p < 0.05;**p < 0.01; ***p < 0.001; ns non-significant.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 47

Metadata

Authors
Biavasco, R., Lettera, E., Giannetti, K., Gilioli, D., Beretta, S., Conti, A., Scala, S., Cesana, D., Gallina, P., Norelli, M., Basso-Ricci, L., Bondanza, A., Cavalli, G., Ponzoni, M., Dagna, L., Doglioni, C., Aiuti, A., Merelli, I., Di Micco, R., & Montini, E.
Affiliations
  • The San Raffaele Telethon Institute for Gene Therapy (IT)
  • Memorial Sloan Kettering Cancer Center (US)
  • Vita-Salute San Raffaele University (IT)
  • IRCCS Ospedale San Raffaele (IT)
  • National Research Council (IT)
Corresponding author
Montini, Eugenio
Venue
Nature Communications
Published
2021-07-27
Volume
12
Issue
1
Pages
4559-4559
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3185327671
Cited by
47
References
34
Citations by year
2026: 5 · 2025: 7 · 2024: 8 · 2023: 9 · 2022: 6 · 2021: 12
FWCI
5.47
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
Funders
Fondazione Telethon (TGT16B01)
Topics
  • Health Sciences › Medicine › Hematology › Histiocytic Disorders and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords
oncogene-induced senescence, hematopoietic stem and progenitor cells, BRAF V600E mutation, histiocytosis, chronic inflammation, TNF-α, senescence-associated secretory phenotype, DNA damage response, bystander cells, humanized mice, bone marrow failure
MeSH terms
Animals, Bone Marrow, Chronic Disease, Gene Expression Regulation, Hematopoiesis, Hematopoietic Stem Cells, Humans, Inflammation, Mutation, Oncogenes, Tumor Necrosis Factor-alpha, Histiocytosis, Lentivirus, Cellular Senescence, Paracrine Communication, Cyclin-Dependent Kinase Inhibitor p16, Myeloid Cells, Principal Component Analysis, Proto-Oncogene Proteins B-raf, Green Fluorescent Proteins, Mice, Cell Cycle Checkpoints

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oncogene-induced senescence in hematopoietic progenitors features myeloid restricted hematopoiesis, chronic inflammation and histiocytosis. https://app.cochat.ai/papers/10.1038/s41467-021-24876-1
The paper
Biavasco, R., Lettera, E., Giannetti, K., Gilioli, D., Beretta, S., Conti, A., Scala, S., Cesana, D., Gallina, P., Norelli, M., Basso-Ricci, L., Bondanza, A., Cavalli, G., Ponzoni, M., Dagna, L., Doglioni, C., Aiuti, A., Merelli, I., Di Micco, R., & Montini, E. (2021). Oncogene-induced senescence in hematopoietic progenitors features myeloid restricted hematopoiesis, chronic inflammation and histiocytosis. Nature Communications. https://doi.org/10.1038/s41467-021-24876-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.